Learn How

Learn how AI can help to promote early diagnosis of HF, reduce HF readmissions, and address avoidable adverse events. Discover how AI can help to identify patients at high risk of HF, predict preventable hospitalization due to HF, and identify complications tied to modifiable risk factors (e.g., poor medication adherence).

Automatically ingest data from dozens of health data sources including...

Medical Claims

Data extracted from health insurance medical claims with details about dates and place of service, diagnosis codes, key procedures, use of medical equipment, and provider specialties.

Rx Claims

Data extracted from health insurance pharmacy claims with details about each medication and its type, fill dates, days supply, pharmacy location, and prescribing clinician.

Electronic Health Records

EHR data with comprehensive patient histories of vital signs and symptoms, problem lists and chief complaints, tests results, diagnoses and procedures, and prescriptions.

nodes
Closedloop icon with a line

ClosedLoop generates explainable predictions using

thousands of auto generated, clinically relevant contributing factors

Camille Phillips
57-Year-Old Female
Risk of admission for acute heart failure in the next 12 months
Risk Score Percentile
98
Impact on Risk  |  Contributing Factor
Value
+27% | # of Acute Decompensated HF Admissions (12M)
2
+19% | Decline in LV Ejection Fraction
0.45 to 0.35
+14% | Adherence to Loop Diuretics
60%
+11% | Hemoglobin (g/dL)
11.5

Why It Matters

Today, approximately 6.5 million adult Americans are living with heart failure (HF).¹ By 2030, this is estimated to rise to 8 million people with total economic costs reaching $70 billion at which point 2.97% of U.S. adults will have HF and 71% of them will be age 65 or older.² With more than one million hospitalizations each year, HF is one of the most common causes of admissions and readmissions and a leading cause of mortality; after a diagnosis of HF, survival estimates are 50% and 10% at five and ten years, respectively.³

Beneficiaries with HF constitute 10.5% of all FFS Medicare beneficiaries and their costs (excluding medications) make up 33.2% of all Medicare costs.⁴  HF is a chronic disease characterized by acute exacerbation, and a major cost driver is treatment for worsening HF and fluid overload, 80% of which occurs in inpatient settings.²𝄒³  

Many instances of hospitalization for HF patients are considered preventable, yet HF remains the leading cause of hospitalization for patients over age 65.²𝄒⁵ HF admissions also generate the highest number and highest rate of 30-day readmissions among Medicare beneficiaries.⁶𝄒⁷  

AI Presents an Opportunity

Organizations can employ predictive analytics to identify high risk HF patients and use insights from AI to enroll patients in care management programs.  Proactively identifying high-risk HF patients and intervening to prevent significant exacerbations that cause hospitalization is essential to improving quality of life and reducing avoidable costs. For example, interventions centered on patient self-management have been shown to reduce the odds of readmission after one year by 40%.⁸ Such programs prevent hospitalizations by strengthening care continuity, improving adherence to complex medication regimens, and ultimately identifying early warning signs more readily. 

Did You Know…

  • 33% of all Medicare costs are for patients with heart failure⁴
  • 10% of HF patients survive 10 years after being diagnosed with HF³ 
  • $70 billion is the projected economic cost in 2030 for patients with HF¹
  • 6.5 million adult Americans are living with heart failure²
expand_more
Citations & Footnotes

1 Benjamin, Emelia J., et al. “Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association.” Circulation, vol. 139, no.10, Jan. 2019, https://www.ahajournals.org/doi/10.1161/CIR.0000000000000659 

2 Fitch K, Lau J, Engel T, Medicis JJ, Mohr JF, Weintraub WS. The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings. ClinicoEconomics and Outcomes Research. 2018;Volume 10:855-863. doi:10.2147/ceor.s184048

3 Roger VL. Epidemiology of Heart Failure. Circulation Research. 2013;113(6):646-659. doi:10.1161/circresaha.113.300268

4 Fitch K, Engel T, Lau J. The Cost Burden of Worsening Heart Failure in the Medicare Fee for Service Population: An Actuarial Analysis. Milliman, Inc; 2017. 

5 Michalsen A, König G, Thimme W. “Preventable causative factors leading to hospital admission with decompensated heart failure.” BJM Journals, Heart, vol. 80, no. 5, Nov. 1998, pp. 437–441. 

6 Jencks, Steven F., et al. “Rehospitalizations among patients in the Medicare fee-for-service program.”  The New England Journal of Medicine, vol. 360, no. 14, Apr. 2009, pp. 418–1428. DOI:10.1056/NEJMsa0803563 

7 Reddy, Yogesh, et al. “Readmissions in Heart Failure: It’s More Than Just the Medicine.” Mayo Clinic Proceedings, vol. 94, no. 10, Oct. 2019, pp. 1919–1921. DOI: https://doi.org/10.1016/j.mayocp.2019.08.015

8 Jovicic, A., et al. “Effects of Self-Management Intervention on Health Outcomes of Patients with Heart Failure: A Systematic Review of Randomized Controlled Trials.” BMC Cardiovasc Disorders, vol. 6, no. 43, 2 Nov. 2006, https://doi.org/10.1186/1471-2261-6-43.

Klas image

ClosedLoop.ai’s healthcare expertise was a big deal to us. It didn’t take a lot to translate things, and they adapted their approach to create a predictive model for our unique interest in the data streams.

Anonymous Customer CEO
KLAS Analyst Report
Cheryl

We are extremely impressed with the predictive modeling capabilities the ClosedLoop platform has delivered. The ClosedLoop team has exceeded all defined goals and benchmarks set to date and we anticipate a substantial return on our investment as these predictions are operationally deployed.

Cheryl Lulias
President & Executive Director, MHN
Klas image

We wanted to use the product for population health and SDOH. The things we can do with the ClosedLoop.ai product are unlimited.

Anonymous Customer
KLAS Analyst Report
image of Jim Walton

Over the course of my career, there has never been an opportunity like this. The need for efficiency is a daunting challenge. The capacity of predictive AI technology drives our efficiency and will have a lasting impact on our ability to help PCPs improve the quality of health outcomes while reducing health disparities.

Dr. Jim Walton
President & CEO, Genesis Physicians Group
image of Drew

ClosedLoop stood out from other AI firms in that they offered not only a usable, flexible analytics platform but extensive healthcare expertise.

Drew Crenshaw
Chief of Population Health, Oak Street Health

Learn What ClosedLoop Can Do for Your Organization

The industry’s best collection of customizable predictive models for common healthcare use cases.

Talk To An Expert